1[1]Packer M,The neurohormonal hypothesis:a theory to explain the mechanism of disease progression in heart failure[J].J Am Coll Cardiol,1992,20∶248.
2[2]Waagstein F,Hjalmarson A,Vamauskas E,et al.Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy[J].Br Heart J,1975,37∶1022-1036.
3[3]Bristow MR.Mechanism of action of betablocking agents in heart failure [J].Am J Cardiol,1997,80(1)∶26-40.
4[4]Colucci W.Molecular and cellular mechanisms of myocardial failure [J].Am J Cardiol,1997,80(1)∶15-25.
5[5]Metra M,Nodari S,D,Aloia A,et al.A rationale for the use of β-blocker as standard trsatmsnt for heart failure[J].Am Heart J,2000,139∶511-521.
6[6]Bristow MD.Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with bsta-blocking agents[J].Am J Cardiol,1993,71∶12c.
8[8]Packer M. β-blocker in heart failure-basic concepts and clinical results[J].Am J Hypertens,1998,11(1)∶23s-37s.
9[9]Packer M,Bristow MR,Cohn IN,et al.Effect of Carvedilol on morbidity and mortality in chronic heart failure[J].N Engl J Med,1996,334(11)∶1349-1355.
10[10]Australia/New Zealand Heart Failure Research.Callaborative group Randomized,placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease[J].Lancet,1997,353(9049)∶375-380.
